NCT00142129View on ClinicalTrials.gov

Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Waldenstrom's MacroglobulinemiaLymphoplasmacytic Lymphoma
Interventions
DRUG

Bortezomib (Velcade)

Trial Locations (2)

02115

Dana-Farber Cancer Center, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors
All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER